hydromorphone immediate release (LTX-04) / Acura Pharma - LARVOL DELTA

Acura Pharmaceutical's Limitx technology successfully demonstrates oral abuse deterrence (MarketWired) - "Acura Pharmaceuticals...today announced that topline interim results from clinical study AP-LTX-400 demonstrated one test formulation of LTX-04...successfully demonstrated the release of the active opioid ingredient was reduced when three intact tablets were ingested but that additional formulation development will be required for LTX-04 to deliver a sufficient amount of the active ingredient to patients when one or two tablets are administered."

PK/PD data • Pain